NCT06298955 - Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

April 30, 2027

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG

OMS906 study drug

OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals

Trial Locations (5)

NOT_YET_RECRUITING

Omeros Investigational Site, Aachen

NOT_YET_RECRUITING

Omeros Investigational Site, Ulm

RECRUITING

Omeros Investigational Site, Lausanne

NOT_YET_RECRUITING

Omeros Investigational Site, Kyiv

NOT_YET_RECRUITING

Omeros Investigational Site, Leeds